Dr. Motzer on HRQOL with pembrolizumab plus lenvatinib in advanced RCC


Robert J. Motzer, MD, discusses health-related quality of life (HRQOL) analyses from the phase 3 CLEAR trial of frontline pembrolizumab (Keytruda) plus lenvatinib (Lenvima) in patients with metastatic renal cell carcinoma (RCC). According to Motzer, the results showed that the combination resulted in similar HRQOL outcomes and disease-related symptom scores as single-agent sunitinib (Sutent). Motzer is the Kidney Cancer Section Head, Genitourinary Oncology Service; and Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center.

Recent Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.